Reports Q1 revenue $201.32M, consensus $194.93M. “We are very proud of our performance in the first quarter which included strong revenue growth and continued progress on profitability. We achieved a tremendous milestone with over 100,000 patients receiving Inspire therapy and we are still just getting started in growing awareness and adoption,” said Tim Herbert, chairman and CEO of Inspire Medical (INSP) Systems. “We are now ready to launch the Inspire V system and look forward to initiating the full launch this month in the U.S.”
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical Systems Reports Strong Q1 2025 Revenue Growth
- INSP Earnings this Week: How Will it Perform?
- Inspire Medical price target lowered to $175 from $190 at Stifel
- Nyxoah price target lowered to $14 from $15 at Stifel
- Inspire Medical adds Paul Hoff, Ruchir Patel as VP, senior medical directors